Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice

Kinya Inoue(University Hospital Kyoto Prefectural University of Medicine), Michio Sata(Kurume University), Hirohisa Yano(Kurume University), Takato Ueno(Kurume University), Tõru Nakamura, Hironori Koga(Kurume University), Osamu Hashimoto(Gifu University), Hiroshi Masuda(Kurume University), Mitsuhiko Abe(Kurume University), Hideki Iwamoto, Takuji Torimura(Omuta hospital)
Clinical Cancer Research
May 20, 2012
10.1158/1078-0432.ccr-11-2041
Cited by 46

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3
|American Journal Of Pathology|2004|536
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504